British manufacturing boosted by further GSK investments

By Dan Stanton

- Last updated on GMT

UK's Patent Box encouraged recent investments, GSK says
UK's Patent Box encouraged recent investments, GSK says

Related tags Investment Uk Gsk

GSK has committed itself to the UK for the long-term with an investment of £200m ($328m) across two of its manufacturing sites.

GSK were at the forefront of pushing the UK government to cut corporate tax on income generated by homegrown products and in April this year the Patent Box​ was introduced, setting the tax level at 10%.

As part of GSK’s ongoing commitment to the UK, the firm announced this morning it was pumping an additional £200m into its Ware, Hertfordshire and Worthing, Sussex sites.

GSK spokesman Kalpesh Joshi told the firm is committed to the UK for the long-term, and this latest announcement comes on the back of a number of recent investments.

“We have a fantastic workforce here in the UK which is important and naturally, the implementation of the patent box has made the UK a more attractive place to invest,”​ he said.

Ware is both an R&D and manufacturing site but the investment will add capability to produce GSK’s respiratory device, the Relvar Ellipta inhaler, which received European Marketing Approval last month.

Furthermore the location is the preferred site for a centre of manufacturing innovation the firm intends to build dedicated to turning new science and technologies into practical manufacturing applications.

Worthing produces both active ingredients and formulated drugs and will benefit from a new bulk sterile building and filling line for the antibiotic Augmentin.

The company initially pledged £370m​ in a new facility in Ulverston, Cumbria which is currently being built, and has spent a further £130m on expanding plants in Montrose and Irvine, both in Scotland. Such investment has created almost 1,000 jobs for the UK, the firm said.

Late last month a further £25m was invested into the API facility​ in Montrose in order to support the delivery of its new pipeline.

Related news

Show more

Related products

show more

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us